세계의 PARP 저해제 바이오마커 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 용도별, 서비스별, 지역별, 전망과 예측(2024-2031년)

The Global PARP Inhibitor Biomarkers Market size is expected to reach $1.6 billion by 2031, rising at a market growth of 8.3% CAGR during the forecast period.

North America boasts advanced healthcare infrastructure, including well-established clinical laboratories, oncology centres, and research institutions. Thus, the North America region acquired 42.5% revenue share in the market 2023. The availability of diagnostic technologies and skilled healthcare professionals enhances the accessibility and utilization of biomarker testing services, driving the demand for it in North America.

Oncology research is continually uncovering new biomarkers associated with cancer development, progression, and response to therapy. As our understanding of the molecular pathways underlying cancer improves, researchers are identifying biomarkers that predict response to specific treatments, including it.

Additionally, point-of-care testing brings diagnostic capabilities closer to the patient, enabling biomarker testing to be performed outside traditional laboratory settings, such as outpatient clinics, physician offices, or even the patient's home. Hence, the expansion of point-of-care testing is raising the market's growth.

However, Biomarker testing often involves sophisticated laboratory techniques and specialized equipment, which can be expensive to procure and maintain. Additionally, the cost of reagents, consumables, and personnel required for biomarker testing adds to the overall expense. In conclusion, the high cost of biomarker testing hinders the market's growth.

Economic hardships and changes in healthcare priorities during the pandemic affected patient access to cancer treatments, including this. Financial constraints, job losses, and changes in insurance coverage may have influenced treatment decisions and patient adherence. Thus, the COVID-19 pandemic had a negative impact on the market.

Product Outlook

Based on product, the market is divided into kits and assays. In 2023, the kits segment garnered 63.8% revenue share in the market. Biomarker testing kits offer a user-friendly and convenient solution for healthcare providers to perform biomarker testing in-house without requiring specialized laboratory infrastructure or expertise.

Application Outlook

Based on application, the market is categorized into breast cancer, ovarian cancer, and others. The ovarian cancer segment witnessed 30.7% revenue share in the market in 2023. PARP inhibitors have demonstrated clinical efficacy in treating ovarian cancer patients with BRCA mutations. Clinical trials have shown that PARP inhibitors.

Services Outlook

On the basis of services, the market is segmented into BRCA 1 & 2 testing, HRD testing, HRR testing, and others. The BRCA 1 & 2 testing segment recorded 41.8% revenue share in the market in 2023. BRCA1 and BRCA2 mutations are strongly associated with increased sensitivity to this in certain cancers, particularly breast and ovarian cancer.

Regional Outlook

Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2023, the Asia Pacific region generated 24.4% revenue share in the market. The Asia Pacific region is experiencing a significant increase in the incidence of cancer, including breast, ovarian, and other cancers associated with PARP inhibitor therapy.

List of Key Companies Profiled

• Myriad Genetics, Inc.
• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• NeoGenomics Laboratories
• Qiagen N.V
• Agilent Technologies, Inc.
• Merck KGaA
• Bayer AG
• AstraZeneca PLC
• GlaxoSmithKline PLC (GSK)

Global PARP Inhibitor Biomarkers Market Report Segmentation

By Product

• Kits
• Assays

By Application

• Breast Cancer
• Ovarian Cancer
• Others

By Services

• BRCA 1 & 2 Testing
• HRD Testing
• HRR Testing
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1.Market Scope & Methodology

• 1.1Market Definition
• 1.2Objectives
• 1.3Market Scope
• 1.4Segmentation
  • 1.4.1Global PARP Inhibitor Biomarkers Market, by Product
  • 1.4.2Global PARP Inhibitor Biomarkers Market, by Application
  • 1.4.3Global PARP Inhibitor Biomarkers Market, by Services
  • 1.4.4Global PARP Inhibitor Biomarkers Market, by Geography
• 1.5Methodology for the research

Chapter 2.Market at a Glance

• 2.1Key Highlights

Chapter 3.Market Overview

• 3.1Introduction
  • 3.1.1Overview
    • 3.1.1.1Market Composition and Scenario
• 3.2Key Factors Impacting the Market
  • 3.2.1Market Drivers
  • 3.2.2Market Restraints
  • 3.2.3Market Opportunities
  • 3.2.4Market Challenges
• 3.3Porter's Five Forces Analysis

Chapter 4.Global PARP Inhibitor Biomarkers Market by Product

• 4.1Global Kits Market by Region
• 4.2Global Assays Market by Region

Chapter 5.Global PARP Inhibitor Biomarkers Market by Application

• 5.1Global Breast Cancer Market by Region
• 5.2Global Ovarian Cancer Market by Region
• 5.3Global Others Market by Region

Chapter 6.Global PARP Inhibitor Biomarkers Market by Services

• 6.1Global BRCA 1 & 2 Testing Market by Region
• 6.2Global HRD Testing Market by Region
• 6.3Global HRR Testing Market by Region
• 6.4Global Others Market by Region

Chapter 7.Global PARP Inhibitor Biomarkers Market by Region

• 7.1North America PARP Inhibitor Biomarkers Market
  • 7.1.1North America PARP Inhibitor Biomarkers Market by Product
    • 7.1.1.1North America Kits Market by Region
    • 7.1.1.2North America Assays Market by Region
  • 7.1.2North America PARP Inhibitor Biomarkers Market by Application
    • 7.1.2.1North America Breast Cancer Market by Country
    • 7.1.2.2North America Ovarian Cancer Market by Country
    • 7.1.2.3North America Others Market by Country
  • 7.1.3North America PARP Inhibitor Biomarkers Market by Services
    • 7.1.3.1North America BRCA 1 & 2 Testing Market by Country
    • 7.1.3.2North America HRD Testing Market by Country
    • 7.1.3.3North America HRR Testing Market by Country
    • 7.1.3.4North America Others Market by Country
  • 7.1.4North America PARP Inhibitor Biomarkers Market by Country
    • 7.1.4.1US PARP Inhibitor Biomarkers Market
      • 7.1.4.1.1US PARP Inhibitor Biomarkers Market by Product
      • 7.1.4.1.2US PARP Inhibitor Biomarkers Market by Application
      • 7.1.4.1.3US PARP Inhibitor Biomarkers Market by Services
    • 7.1.4.2Canada PARP Inhibitor Biomarkers Market
      • 7.1.4.2.1Canada PARP Inhibitor Biomarkers Market by Product
      • 7.1.4.2.2Canada PARP Inhibitor Biomarkers Market by Application
      • 7.1.4.2.3Canada PARP Inhibitor Biomarkers Market by Services
    • 7.1.4.3Mexico PARP Inhibitor Biomarkers Market
      • 7.1.4.3.1Mexico PARP Inhibitor Biomarkers Market by Product
      • 7.1.4.3.2Mexico PARP Inhibitor Biomarkers Market by Application
      • 7.1.4.3.3Mexico PARP Inhibitor Biomarkers Market by Services
    • 7.1.4.4Rest of North America PARP Inhibitor Biomarkers Market
      • 7.1.4.4.1Rest of North America PARP Inhibitor Biomarkers Market by Product
      • 7.1.4.4.2Rest of North America PARP Inhibitor Biomarkers Market by Application
      • 7.1.4.4.3Rest of North America PARP Inhibitor Biomarkers Market by Services
• 7.2Europe PARP Inhibitor Biomarkers Market
  • 7.2.1Europe PARP Inhibitor Biomarkers Market by Product
    • 7.2.1.1Europe Kits Market by Country
    • 7.2.1.2Europe Assays Market by Country
  • 7.2.2Europe PARP Inhibitor Biomarkers Market by Application
    • 7.2.2.1Europe Breast Cancer Market by Country
    • 7.2.2.2Europe Ovarian Cancer Market by Country
    • 7.2.2.3Europe Others Market by Country
  • 7.2.3Europe PARP Inhibitor Biomarkers Market by Services
    • 7.2.3.1Europe BRCA 1 & 2 Testing Market by Country
    • 7.2.3.2Europe HRD Testing Market by Country
    • 7.2.3.3Europe HRR Testing Market by Country
    • 7.2.3.4Europe Others Market by Country
  • 7.2.4Europe PARP Inhibitor Biomarkers Market by Country
    • 7.2.4.1Germany PARP Inhibitor Biomarkers Market
      • 7.2.4.1.1Germany PARP Inhibitor Biomarkers Market by Product
      • 7.2.4.1.2Germany PARP Inhibitor Biomarkers Market by Application
      • 7.2.4.1.3Germany PARP Inhibitor Biomarkers Market by Services
    • 7.2.4.2UK PARP Inhibitor Biomarkers Market
      • 7.2.4.2.1UK PARP Inhibitor Biomarkers Market by Product
      • 7.2.4.2.2UK PARP Inhibitor Biomarkers Market by Application
      • 7.2.4.2.3UK PARP Inhibitor Biomarkers Market by Services
    • 7.2.4.3France PARP Inhibitor Biomarkers Market
      • 7.2.4.3.1France PARP Inhibitor Biomarkers Market by Product
      • 7.2.4.3.2France PARP Inhibitor Biomarkers Market by Application
      • 7.2.4.3.3France PARP Inhibitor Biomarkers Market by Services
    • 7.2.4.4Russia PARP Inhibitor Biomarkers Market
      • 7.2.4.4.1Russia PARP Inhibitor Biomarkers Market by Product
      • 7.2.4.4.2Russia PARP Inhibitor Biomarkers Market by Application
      • 7.2.4.4.3Russia PARP Inhibitor Biomarkers Market by Services
    • 7.2.4.5Spain PARP Inhibitor Biomarkers Market
      • 7.2.4.5.1Spain PARP Inhibitor Biomarkers Market by Product
      • 7.2.4.5.2Spain PARP Inhibitor Biomarkers Market by Application
      • 7.2.4.5.3Spain PARP Inhibitor Biomarkers Market by Services
    • 7.2.4.6Italy PARP Inhibitor Biomarkers Market
      • 7.2.4.6.1Italy PARP Inhibitor Biomarkers Market by Product
      • 7.2.4.6.2Italy PARP Inhibitor Biomarkers Market by Application
      • 7.2.4.6.3Italy PARP Inhibitor Biomarkers Market by Services
    • 7.2.4.7Rest of Europe PARP Inhibitor Biomarkers Market
      • 7.2.4.7.1Rest of Europe PARP Inhibitor Biomarkers Market by Product
      • 7.2.4.7.2Rest of Europe PARP Inhibitor Biomarkers Market by Application
      • 7.2.4.7.3Rest of Europe PARP Inhibitor Biomarkers Market by Services
• 7.3Asia Pacific PARP Inhibitor Biomarkers Market
  • 7.3.1Asia Pacific PARP Inhibitor Biomarkers Market by Product
    • 7.3.1.1Asia Pacific Kits Market by Country
    • 7.3.1.2Asia Pacific Assays Market by Country
  • 7.3.2Asia Pacific PARP Inhibitor Biomarkers Market by Application
    • 7.3.2.1Asia Pacific Breast Cancer Market by Country
    • 7.3.2.2Asia Pacific Ovarian Cancer Market by Country
    • 7.3.2.3Asia Pacific Others Market by Country
  • 7.3.3Asia Pacific PARP Inhibitor Biomarkers Market by Services
    • 7.3.3.1Asia Pacific BRCA 1 & 2 Testing Market by Country
    • 7.3.3.2Asia Pacific HRD Testing Market by Country
    • 7.3.3.3Asia Pacific HRR Testing Market by Country
    • 7.3.3.4Asia Pacific Others Market by Country
  • 7.3.4Asia Pacific PARP Inhibitor Biomarkers Market by Country
    • 7.3.4.1China PARP Inhibitor Biomarkers Market
      • 7.3.4.1.1China PARP Inhibitor Biomarkers Market by Product
      • 7.3.4.1.2China PARP Inhibitor Biomarkers Market by Application
      • 7.3.4.1.3China PARP Inhibitor Biomarkers Market by Services
    • 7.3.4.2Japan PARP Inhibitor Biomarkers Market
      • 7.3.4.2.1Japan PARP Inhibitor Biomarkers Market by Product
      • 7.3.4.2.2Japan PARP Inhibitor Biomarkers Market by Application
      • 7.3.4.2.3Japan PARP Inhibitor Biomarkers Market by Services
    • 7.3.4.3India PARP Inhibitor Biomarkers Market
      • 7.3.4.3.1India PARP Inhibitor Biomarkers Market by Product
      • 7.3.4.3.2India PARP Inhibitor Biomarkers Market by Application
      • 7.3.4.3.3India PARP Inhibitor Biomarkers Market by Services
    • 7.3.4.4South Korea PARP Inhibitor Biomarkers Market
      • 7.3.4.4.1South Korea PARP Inhibitor Biomarkers Market by Product
      • 7.3.4.4.2South Korea PARP Inhibitor Biomarkers Market by Application
      • 7.3.4.4.3South Korea PARP Inhibitor Biomarkers Market by Services
    • 7.3.4.5Singapore PARP Inhibitor Biomarkers Market
      • 7.3.4.5.1Singapore PARP Inhibitor Biomarkers Market by Product
      • 7.3.4.5.2Singapore PARP Inhibitor Biomarkers Market by Application
      • 7.3.4.5.3Singapore PARP Inhibitor Biomarkers Market by Services
    • 7.3.4.6Malaysia PARP Inhibitor Biomarkers Market
      • 7.3.4.6.1Malaysia PARP Inhibitor Biomarkers Market by Product
      • 7.3.4.6.2Malaysia PARP Inhibitor Biomarkers Market by Application
      • 7.3.4.6.3Malaysia PARP Inhibitor Biomarkers Market by Services
    • 7.3.4.7Rest of Asia Pacific PARP Inhibitor Biomarkers Market
      • 7.3.4.7.1Rest of Asia Pacific PARP Inhibitor Biomarkers Market by Product
      • 7.3.4.7.2Rest of Asia Pacific PARP Inhibitor Biomarkers Market by Application
      • 7.3.4.7.3Rest of Asia Pacific PARP Inhibitor Biomarkers Market by Services
• 7.4LAMEA PARP Inhibitor Biomarkers Market
  • 7.4.1LAMEA PARP Inhibitor Biomarkers Market by Product
    • 7.4.1.1LAMEA Kits Market by Country
    • 7.4.1.2LAMEA Assays Market by Country
  • 7.4.2LAMEA PARP Inhibitor Biomarkers Market by Application
    • 7.4.2.1LAMEA Breast Cancer Market by Country
    • 7.4.2.2LAMEA Ovarian Cancer Market by Country
    • 7.4.2.3LAMEA Others Market by Country
  • 7.4.3LAMEA PARP Inhibitor Biomarkers Market by Services
    • 7.4.3.1LAMEA BRCA 1 & 2 Testing Market by Country
    • 7.4.3.2LAMEA HRD Testing Market by Country
    • 7.4.3.3LAMEA HRR Testing Market by Country
    • 7.4.3.4LAMEA Others Market by Country
  • 7.4.4LAMEA PARP Inhibitor Biomarkers Market by Country
    • 7.4.4.1Brazil PARP Inhibitor Biomarkers Market
      • 7.4.4.1.1Brazil PARP Inhibitor Biomarkers Market by Product
      • 7.4.4.1.2Brazil PARP Inhibitor Biomarkers Market by Application
      • 7.4.4.1.3Brazil PARP Inhibitor Biomarkers Market by Services
    • 7.4.4.2Argentina PARP Inhibitor Biomarkers Market
      • 7.4.4.2.1Argentina PARP Inhibitor Biomarkers Market by Product
      • 7.4.4.2.2Argentina PARP Inhibitor Biomarkers Market by Application
      • 7.4.4.2.3Argentina PARP Inhibitor Biomarkers Market by Services
    • 7.4.4.3UAE PARP Inhibitor Biomarkers Market
      • 7.4.4.3.1UAE PARP Inhibitor Biomarkers Market by Product
      • 7.4.4.3.2UAE PARP Inhibitor Biomarkers Market by Application
      • 7.4.4.3.3UAE PARP Inhibitor Biomarkers Market by Services
    • 7.4.4.4Saudi Arabia PARP Inhibitor Biomarkers Market
      • 7.4.4.4.1Saudi Arabia PARP Inhibitor Biomarkers Market by Product
      • 7.4.4.4.2Saudi Arabia PARP Inhibitor Biomarkers Market by Application
      • 7.4.4.4.3Saudi Arabia PARP Inhibitor Biomarkers Market by Services
    • 7.4.4.5South Africa PARP Inhibitor Biomarkers Market
      • 7.4.4.5.1South Africa PARP Inhibitor Biomarkers Market by Product
      • 7.4.4.5.2South Africa PARP Inhibitor Biomarkers Market by Application
      • 7.4.4.5.3South Africa PARP Inhibitor Biomarkers Market by Services
    • 7.4.4.6Nigeria PARP Inhibitor Biomarkers Market
      • 7.4.4.6.1Nigeria PARP Inhibitor Biomarkers Market by Product
      • 7.4.4.6.2Nigeria PARP Inhibitor Biomarkers Market by Application
      • 7.4.4.6.3Nigeria PARP Inhibitor Biomarkers Market by Services
    • 7.4.4.7Rest of LAMEA PARP Inhibitor Biomarkers Market
      • 7.4.4.7.1Rest of LAMEA PARP Inhibitor Biomarkers Market by Product
      • 7.4.4.7.2Rest of LAMEA PARP Inhibitor Biomarkers Market by Application
      • 7.4.4.7.3Rest of LAMEA PARP Inhibitor Biomarkers Market by Services

Chapter 8.Company Profiles

• 8.1Myriad Genetics, Inc.
  • 8.1.1Company Overview
  • 8.1.2Financial Analysis
  • 8.1.3Research & Development Expenses
• 8.2Thermo Fisher Scientific, Inc.
  • 8.2.1Company Overview
  • 8.2.2Financial Analysis
  • 8.2.3Segmental and Regional Analysis
  • 8.2.4Research & Development Expenses
  • 8.2.5SWOT Analysis
• 8.3Illumina, Inc.
  • 8.3.1Company Overview
  • 8.3.2Financial Analysis
  • 8.3.3Segment and Regional Analysis
  • 8.3.4Research & Development Expense
  • 8.3.5SWOT Analysis
• 8.4Neogenomics, Inc.
  • 8.4.1Company Overview
  • 8.4.2Financial Analysis
  • 8.4.3Segmental and Regional Analysis
  • 8.4.4Research & Development Expenses
• 8.5Qiagen N.V.
  • 8.5.1Company Overview
  • 8.5.2Financial Analysis
  • 8.5.3Regional Analysis
  • 8.5.4Research & Development Expense
  • 8.5.5SWOT Analysis
• 8.6Agilent Technologies, Inc.
  • 8.6.1Company Overview
  • 8.6.2Financial Analysis
  • 8.6.3Segmental and Regional Analysis
  • 8.6.4Research & Development Expense
  • 8.6.5SWOT Analysis
• 8.7Merck KGaA
  • 8.7.1Company Overview
  • 8.7.2Financial Analysis
  • 8.7.3Segmental and Regional Analysis
  • 8.7.4Research & Development Expense
  • 8.7.5SWOT Analysis
• 8.8Bayer AG
  • 8.8.1Company Overview
  • 8.8.2Financial Analysis
  • 8.8.3Segmental and Regional Analysis
  • 8.8.4Research & Development Expense
  • 8.8.5SWOT Analysis
• 8.9AstraZeneca PLC
  • 8.9.1Company Overview
  • 8.9.2Financial Analysis
  • 8.9.3Regional Analysis
  • 8.9.4Research & Development Expenses
  • 8.9.5SWOT Analysis
• 8.10.GlaxoSmithKline PLC (GSK)
  • 8.10.1Company Overview
  • 8.10.2Financial Analysis
  • 8.10.3Regional Analysis
  • 8.10.4Research & Development Expense
  • 8.10.5SWOT Analysis

Chapter 9.Winning Imperatives of PARP Inhibitor Biomarkers Market